Related Experiment Video
Updated: Jan 21, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
[Research Progress of Ras/Raf/MEK/ERK Signaling Pathways in Leukemia-Review]
Jing Liu1, Na Lv1, Yong-Hui Li1
1Medical College of Chinese PLA, Department of Hematology of Chinese PLA General Hospital, Beijing 100853, China.
Abstract:
Ras/Raf/MEK/ERK signaling pathway plays an important role in the occurrence and development of leukemia. Using the inhibitors of key signaling components in the signaling pathway is new strategy for the treatment of leukemia. In recent years, the screening of these inhibitors and their in vitro and in vivo researches have become a hot spot in the field of treatment. In vivo and in vitro experiments and early clinical studies have shown that these inhibitors have good effect and application prospects in the treatment of leukemia. This review focuses on the recent advances of the role of Ras/Raf/MEK/ERK signaling pathway in the occurence, development and treatment of leukemia.
Insights
Targeting the Ras/Raf/MEK/ERK pathway with inhibitors is a promising new strategy for leukemia treatment. Recent research, including in vitro, in vivo, and early clinical studies, shows significant therapeutic potential.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The Ras/Raf/MEK/ERK signaling pathway is crucial in leukemia development.
- Targeting this pathway presents a novel therapeutic strategy for leukemia.
Purpose of the Study:
- To review recent advances in understanding the Ras/Raf/MEK/ERK pathway's role in leukemia.
- To highlight the therapeutic potential of pathway inhibitors in leukemia treatment.
Main Methods:
- Literature review of in vitro and in vivo studies.
- Analysis of early clinical trial data.
- Focus on inhibitors targeting key signaling components.
Main Results:
- Inhibitors of the Ras/Raf/MEK/ERK pathway show efficacy in preclinical models.
- Early clinical studies indicate positive outcomes and therapeutic prospects.
- Pathway inhibition is an emerging and effective treatment strategy.
Conclusions:
- The Ras/Raf/MEK/ERK pathway is a validated target for leukemia therapy.
- Inhibitors targeting this pathway demonstrate significant therapeutic promise.
- Further research and clinical application of these inhibitors are warranted.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Hedgehog Signaling Pathway
The Ras Gene
Ras is a...
Insulin: The Receptor and Signaling Pathways

